Skip to content
TrialMatch
Sign up
Recruiting

PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity than MRI alone for identifying recurrence or failure in patients undergoing focal therapy.

Condition
Prostate Cancer
Sponsor
NYU Langone Health

Who can join

Age
40 to 95 years
Sex
Male only
Healthy volunteers
Not stated

Inclusion 11

  • Minimum age: 40 years
  • Maximum age: 95 years
  • Eligible sex: Male
  • Study condition: Prostate Cancer
  • Male patients 40-95 years of age with biopsy-confirmed localized prostate cancer.
  • Grade Group ≥2 (Gleason score 3+4 or higher).
  • Unifocal disease visible on mpMRI.
  • Patients undergoing HIFU as part of their standard of care
  • PSA \<20 ng/mL.
  • No metastatic disease on PSMA PET/CT
  • Willingness to comply with follow-up protocols (PSA testing, imaging, biopsies).

Exclusion 3

  • Evidence of metastatic disease on PSMA PET/CT.
  • Allergy to POSLUMA or gadolinium.
  • Inability to tolerate MRI due to claustrophobia or posture/back-hip issues.

Where

1 site, 1 recruiting

NYU Langone Health

New York, New York, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.